Flagship record · Pramlintide

Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.

reviewnarrative reviewcontextual mention

Scientific attribution

The source provides review, development, protocol, or other contextual evidence rather than a peptide-specific primary intervention.

PMID: 40360789
DOI: 10.1038/s41574-025-01125-9
Sample size: Not captured in the structured review record
Population / model: Pramlintide was approved by the FDA in 2005 for the treatment of type 1 diabetes mellitus and insulin-requiring type 2 diabetes, and was also explored as a novel anti-obesity treatment.

Review status

This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.

Loading research intelligence

Preparing the structured Flagship evidence library.

Flagship record · Pramlintide

Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus.

reviewnarrative reviewcontextual mention

Scientific attribution

The source provides review, development, protocol, or other contextual evidence rather than a peptide-specific primary intervention.

PMID: 40360789
DOI: 10.1038/s41574-025-01125-9
Sample size: Not captured in the structured review record
Population / model: Pramlintide was approved by the FDA in 2005 for the treatment of type 1 diabetes mellitus and insulin-requiring type 2 diabetes, and was also explored as a novel anti-obesity treatment.